Core Viewpoint - The study reveals that the natural small molecule Lawsone, derived from the plant Impatiens, can enhance the antitumor activity and stem-like properties of CD8⁺ T cells by modulating the NQO1 enzyme and driving metabolic reprogramming through the pentose phosphate pathway (PPP) [2][3][12]. Group 1: Mechanism of Action - Lawsone hijacks the NQO1 enzyme in T cells, inducing redox cycling that enhances the PPP, thereby conferring unique stem-like properties and mitochondrial adaptability to effector CD8⁺ T cells [3][10]. - The Law-NQO1 signaling axis exhibits a biphasic regulation pattern: initially amplifying PPP activity and mROS levels to drive T cell differentiation, followed by a sustained phase that enhances cell proliferation and maintains stemness [10][14]. Group 2: Clinical Implications - The strategy shows strong clinical translation potential, as simple pharmacological pre-treatment of tumor-specific T cells with Lawsone significantly improves their tumor-killing efficiency and persistence in vivo without notable systemic toxicity [12][15]. - This research highlights NQO1 as a new immune metabolic checkpoint and provides a straightforward, cost-effective optimization strategy for T cell therapy without complex genetic modifications [15].

Core Viewpoint - The research highlights a novel approach to enhance mRNA vaccine efficacy by reprogramming dendritic cell metabolism using crosslinked ionizable lipids, specifically C12-2aN, which opens new avenues for the development of next-generation mRNA-LNPs [4][5][9]. Group 1: Research Findings - The study developed a crosslinked ionizable lipid, C12-2aN, which possesses intrinsic metabolic regulatory properties, enhancing mRNA vaccine effectiveness through metabolic reprogramming of dendritic cells [5][7]. - C12-2aN LNPs demonstrated superior vaccine efficacy in SARS-CoV-2 and OVA tumor models, showing stronger neutralization capacity against pseudovirus infections and significantly improved survival rates compared to control LNPs without crosslinking [7][9]. - The C12-2aN LNPs outperformed FDA-approved LNPs in reducing off-target delivery and minimizing immunogenicity, indicating a significant advancement in mRNA vaccine safety and effectiveness [9]. Group 2: Methodology - The research utilized imidoester-based coupling chemistry to design the crosslinked ionizable lipid, which not only serves as an mRNA carrier but also acts as a metabolic regulator by activating the mTORC2 pathway to stimulate glycolysis [7]. - The innovative chemical design of the new LNP allows for an "active" enhancement of immune responses by modulating the metabolic state of dendritic cells, marking a significant step forward in mRNA vaccine technology [9].

Core Viewpoint - The study identifies IGF2BP3 as a key regulatory factor in the aging of human adipose-derived stem cells (hASC), linking m6A epitranscriptomic modifications with metabolic reprogramming, and establishes the IGF2BP3-m6A-BCAT1/GLS signaling axis as a potential therapeutic target for enhancing tissue regeneration in aged hASC [4][8]. Group 1 - Aging impairs the regenerative capacity and differentiation potential of human adipose-derived stem cells (hASC), but the underlying mechanisms remain unclear [2][6]. - The research demonstrates that IGF2BP3-dependent glutamine and branched-chain amino acid (BCAA) metabolic reprogramming rejuvenates aged hASC, enhancing their tissue regeneration capabilities [3][4]. - A metabolically active subpopulation of hASC, characterized by increased BCAA and glutamine metabolism, is primarily found in infant-derived hASC, indicating a link between metabolic activity and stem cell youthfulness [7]. Group 2 - The study reveals that the decline of the IGF2BP3-m6A-BCAT1/GLS signaling axis with age leads to functional deterioration in aged hASC [7][8]. - Rescue experiments indicate that restoring BCAT1/GLS or supplementing with BCAA/glutamine can significantly rejuvenate aged hASC, improving their proliferation, differentiation, and wound healing abilities [7][8]. - The research proposes two therapeutic strategies: nutritional supplementation to address metabolic deficiencies and m6A regulation to stabilize key mRNA, providing clinically feasible solutions for optimizing aged hASC for tissue regeneration [8].

Core Viewpoint - Obesity is a significant global public health crisis linked to various chronic diseases, characterized by persistent low-grade inflammation that exacerbates disease progression [6][7]. Group 1: Research Findings - A study published in Science reveals that obesity reshapes macrophage nucleotide metabolism, leading to hyperactivation of the NLRP3 inflammasome and uncontrolled inflammation, accelerating disease progression [3][4]. - The study identifies SAMHD1 as an intrinsic inhibitor in macrophages that can suppress NLRP3 inflammasome activation across species from fish to humans [3]. Group 2: Mechanisms of Inflammation - The NLRP3 inflammasome acts as an "alarm" in the immune system, activated by tissue damage or stress, producing pro-inflammatory cytokines like IL-1β, which, in obesity, disrupt insulin signaling and accelerate metabolic diseases [9]. - Obese individuals exhibit an increased amount of oxidized mitochondrial DNA (ox-mtDNA) in their immune cells, which activates the NLRP3 inflammasome [11][12]. Group 3: Role of SAMHD1 - SAMHD1 is crucial for maintaining nucleotide balance in cells, and obesity leads to its phosphorylation and functional impairment, resulting in excessive NLRP3 inflammasome activation [14]. - The absence of functional SAMHD1 in animal models leads to NLRP3 hyperactivation, indicating its role as a regulatory mechanism against inflammation [14]. Group 4: Metabolic Reprogramming - Obesity alters the metabolic pathways in immune cells, allowing excess dNTPs to enter mitochondria via nucleotide transport proteins, bypassing normal synthesis pathways and leading to uncontrolled mtDNA synthesis [16]. - Blocking dNTP transport into mitochondria can reverse obesity-related inflammation, suggesting a potential therapeutic direction [16]. Group 5: Clinical Implications - Mice lacking SAMHD1 exhibit typical metabolic abnormalities after a high-fat diet, and blocking dNTP transport alleviates these symptoms [18]. - The study's findings indicate that targeting mitochondrial dNTP transport could lead to new therapies for chronic inflammation and metabolic diseases associated with obesity, offering a more precise approach than traditional immune response suppression methods [18].

Core Insights - The article discusses the anticipated hot research areas for the National Natural Science Foundation of China (NSFC) funding in 2026, emphasizing the importance of understanding these trends for project design [4][5]. Group 1: Core Mechanisms - Key focus areas include immune regulation (macrophage polarization, neutrophil function, T-cell exhaustion), mitochondrial function and homeostasis, novel cell death mechanisms (ferroptosis, pyroptosis), metabolic reprogramming (glycolysis, lactylation), and post-translational modifications of proteins (ubiquitination, SUMOylation) [4]. Group 2: Frontier Interdisciplinary Areas - Emerging fields highlighted are epitranscriptomics (RNA modifications like m6A, m7G), intercellular communication (exosomes), host-microbiome interactions (gut microbiota), and stem cells with regenerative medicine [5]. Group 3: Key Technologies - Important technological advancements include single-cell and spatial multi-omics, organoids and disease models, and AI/machine learning-driven target discovery and data analysis [5]. Group 4: Research Case Studies - The article presents several research cases that exemplify how researchers are engaging with these hot topics, including: - Neutrophils and their role in thrombosis, published in the European Heart Journal [12]. - Immune evasion mechanisms in tumors, published in Cell [13]. - Gut microbiota's role in Crohn's disease, published in Gut [14]. - Glycolysis and its implications in cancer, published in Signal Transduction and Targeted Therapy [14]. - Development of organoids for bone repair, published in Advanced Materials [14].

Core Viewpoint - The study published in Cell highlights that chronic metabolic stress from high-fat diets not only leads to fatty liver but also induces profound changes in liver stem cells, which can promote tumorigenesis [1][2]. Group 1: Research Findings - Chronic stress forces liver cells to choose between survival and maintaining organ function, leading to early adaptive changes that can "pre-program" future tumor development [3][4]. - The research utilized a high-fat diet mouse model to simulate human metabolic dysfunction related to fatty liver disease, tracking changes in liver cells through multi-omics analysis [5]. - Chronic metabolic stress activates two core programs in liver cells: an upregulation program that promotes cell survival and regeneration while downregulating liver-specific functions, leading to decreased liver function [6]. Group 2: Key Mechanisms - The decline of the ketogenesis rate-limiting enzyme HMGCS2 is crucial, as its knockout in liver cells under high-fat diet stress exacerbates stress responses and significantly increases tumor incidence [8]. - The transcription factors SOX4 and RELB play a central role in promoting liver cell dedifferentiation and proliferation under stress, with high expression levels in patients with metabolic dysfunction-associated fatty liver disease (MASLD) indicating poor prognosis [10]. Group 3: Clinical Implications - The study reveals a "memory effect" of chronic stress and suggests monitoring the expression of genes like HMGCS2 and SOX4 as early risk markers for liver cancer [14]. - Targeting metabolic pathways, such as ketogenesis, or transcription factors like SOX4 may block precancerous states, providing potential intervention strategies [15]. - Overall, the adaptation of the liver to chronic metabolic stress enhances short-term cell survival but sacrifices long-term liver function, emphasizing the importance of healthy diets and metabolic stress control in preventing liver cancer [17].

Core Insights - The article discusses a new research study that addresses the impaired cellular behavior during the healing process in the elderly, focusing on the role of pro-inflammatory macrophages and aging stem cells in tissue regeneration [2][6]. Group 1: Research Findings - A research team from Zhejiang University and affiliated hospitals developed a spatiotemporal-adaptive nanotherapeutic system that utilizes a glucose-modified mixed membrane delivery strategy to precisely regulate metabolic reprogramming [3][6]. - The system employs NAD+ loaded ZIF-8 nanoparticles (NZM) to target pro-inflammatory macrophages during the inflammatory phase, triggering the release of NAD+ and inducing an anti-inflammatory transition [6]. - In the repair phase, the system restores NAD+ levels in aging stem cells, promoting tissue regeneration [6]. Group 2: Implications and Applications - The study demonstrates that the NAD+ can reprogram dysfunctional cells, effectively reshaping the multicellular regenerative microenvironment [6]. - The proposed strategy has shown to restore bone regeneration capabilities in osteoporotic mice and accelerate skin wound healing [6][7]. - This research connects cellular metabolism, nanomedicine, and regenerative therapy, offering a promising and translatable new strategy for precise clinical interventions [7].

Core Viewpoint - The research identifies a metabolic vulnerability in glioblastoma, revealing that the tumor relies on "stealing" serine from its environment for rapid growth, which can be targeted for treatment [4][8]. Group 1: Research Findings - Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, with standard treatments including surgery, radiotherapy, and temozolomide chemotherapy, but it often recurs, leading to a high mortality rate within 1-2 years post-diagnosis [3]. - The study published in Nature highlights that glioblastoma tumors can utilize serine from their surroundings instead of synthesizing it, presenting a critical metabolic weakness [4][8]. - By feeding glioblastoma mouse models a diet lacking serine, researchers observed a slowdown in tumor growth and spread, extending survival time [4][8]. Group 2: Metabolic Mechanism - The research team analyzed samples from eight glioblastoma patients and found that tumors utilize glucose from the environment to synthesize essential components like DNA, facilitating aggressive growth [6][7]. - In healthy brain tissue, glucose is metabolized for the tricarboxylic acid (TCA) cycle and converted into serine, while glioblastoma bypasses serine synthesis by "stealing" it, allowing glucose to be redirected for synthesizing nucleotides necessary for cancer cell proliferation [7][8]. Group 3: Clinical Implications - The study suggests that the reliance on serine presents a targetable metabolic vulnerability, and the team plans to conduct clinical trials on a serine-restricted diet for patients, which, while not curative, could provide additional time for some patients [8].

Core Viewpoint - The study highlights the role of C19orf12 as a mitochondrial metabolic regulator in non-small cell lung cancer (NSCLC), indicating that elevated expression levels may serve as a biomarker for improved response to metformin treatment [10]. Group 1: Research Findings - C19orf12 is highly expressed in NSCLC and is associated with poor prognosis [7]. - C19orf12 regulates mitochondrial function and drives glucose metabolic reprogramming [7]. - C19orf12 interacts with LRPPRC protein, downregulating the expression of mitochondrial electron transport chain complexes I and IV [7]. - High levels of C19orf12 inhibit mitochondrial respiration and reduce glucose flux through the tricarboxylic acid (TCA) cycle [5][6]. Group 2: Implications for Treatment - C19orf12 enhances the sensitivity of NSCLC cells to the antitumor effects of metformin [6]. - The study suggests that C19orf12 expression levels could predict the response to metformin treatment in NSCLC patients [10].

Core Viewpoint - The study reveals that RIOK1 phase separation restricts PTEN translation via stress granules, promoting tumor growth in hepatocellular carcinoma (HCC) [4][12]. Group 1: Mechanism of Drug Resistance - RIOK1 phase separation mediates the formation of stress granules under TKI treatment stress, recruiting IGF2BP1 and G3BP1 to form dynamic stress granules [11]. - Stress granules selectively encapsulate PTEN mRNA, inhibiting its translation into PTEN protein, leading to the inactivation of the PTEN/PI3K/AKT pathway [11]. - The loss of PTEN activates the pentose phosphate pathway (PPP), increasing NADPH production and antioxidant capacity, helping cancer cells eliminate TKI-induced reactive oxygen species (ROS) [11]. Group 2: Key Findings and Clinical Relevance - The NRF2-RIOK1 regulatory axis is activated by oxidative stress (e.g., TKI treatment), upregulating RIOK1 expression and enhancing cancer cell adaptability through a positive feedback loop [11]. - The study establishes a causal chain linking stress granules, metabolic reprogramming, and TKI treatment resistance in HCC [12]. Group 3: Research Significance and Translational Directions - Targeting RIOK1 phase separation may disrupt the cancer cell's "stress buffering system," providing a new direction to improve TKI efficacy [12]. - Combination therapy of TKI and Chidamide may synergistically enhance anti-tumor effects [13]. - RIOK1 expression levels or the dynamics of stress granules could serve as predictive biomarkers for TKI efficacy, guiding personalized treatment [13].